The storied success of copyright’s flagship drug has undeniably shaped the pharmaceutical landscape. However, investing in companies heavily dependent on biosimilars and the diminishing patent protection https://socialaffluent.com/story6996545/the-blue-pill-and-pharma-a-uncertain-opportunity